The UK government has published a decision on triheptanoin for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), a group of rare inherited metabolic conditions affecting both adults and children. The decision highlights the continuing expansion of rare disease treatments entering the pharmaceutical supply chain — and the operational demands they place on dispensing pharmacies.
What is LC-FAOD?
Long-chain fatty acid oxidation disorders are a group of rare inherited conditions in which the body cannot properly break down long-chain fatty acids to produce energy. Symptoms can include hypoglycaemia, muscle weakness, cardiomyopathy, and rhabdomyolysis. LC-FAOD typically presents in infancy or early childhood, though milder forms may not be diagnosed until adulthood.
Triheptanoin is an oral liquid medicine that provides an alternative energy source — medium odd-chain fatty acids — bypassing the metabolic block. It has been available in some markets under emergency access programmes and is now subject to a formal UK regulatory and access decision.
Why this matters for community pharmacy
While LC-FAOD is rare — estimated to affect fewer than 1 in 10,000 births across all subtypes — the broader trend of rare disease medicines entering routine dispensing has practical implications for community pharmacies:
Unfamiliar formulations and storage requirements. Triheptanoin is an oral liquid, but many rare disease medicines come as reconstituted powders, enzyme replacement infusions, or temperature-sensitive biologics. Pharmacies dispensing these products for the first time may need to review cold chain procedures, storage capacity, and handling protocols.
Patient counselling complexity. Patients with rare diseases often have deep knowledge of their condition but may encounter pharmacists unfamiliar with their treatment. Providing confident, accurate counselling on administration, side effects, and interactions requires preparation that goes beyond a standard PIL review.
Supply chain and specials. Rare disease medicines are frequently supplied through specialist distributors or homecare companies rather than standard wholesalers. Community pharmacies may need to establish new supply relationships or work with hospital pharmacy teams to coordinate dispensing.
Monitoring and shared care. Some rare disease treatments require regular blood tests or clinical monitoring. Where shared care protocols exist between specialist centres and primary care, the community pharmacist plays a coordinating role — checking that monitoring is up to date before dispensing.
The scale of rare disease in the UK
According to Rare Disease UK, approximately 3.5 million people in the United Kingdom live with a rare disease, with over 7,000 distinct conditions identified. The NHS England Rare Disease Framework, published in 2021, committed to improving diagnosis times, access to treatment, and coordination of care — all of which have implications for pharmacy services.
The pipeline of approved rare disease medicines has accelerated in recent years, driven by the Medicines and Healthcare products Regulatory Agency's (MHRA) innovative licensing pathways and NICE's managed access agreements. Each new approval potentially brings a previously hospital-only medication into the community pharmacy supply chain.
What pharmacies can do
Pharmacies that wish to prepare for rare disease dispensing can:
- Review the MHRA's published decisions on new medicines to identify treatments likely to enter community dispensing
- Check cold chain and storage compliance to ensure capacity for temperature-sensitive products
- Engage with local specialist centres to understand shared care protocols for rare disease patients in their area
- Invest in CPD — the Centre for Pharmacy Postgraduate Education (CPPE) offers modules on rare disease awareness and specialist dispensing
For pharmacists interested in specialist clinical roles — including rare disease pharmacy — PharmSee's job search tracks vacancies across NHS trusts, and salary data for specialist pharmacist roles shows what these positions currently pay.
Sources: Triheptanoin decision — GOV.UK; Rare Disease UK; NHS England Rare Disease Framework (2021); PharmSee vacancy data (April 2026).